Heron Therapeutics market cap HRTX
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $56M
- Highest close in our data
- $3.1B
- Aug 2018
Heron Therapeutics is worth $56M at the close on Nov 2, 2026, at $0.30 a share.
That is down 72% over the last year and down 96% over five years.
Its highest close in our data was $3.1B in Aug 2018.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $56M | $52.7M | $273.2M | −76% |
| 2025 | $234.7M | $177.8M | $376.3M | −0% |
| 2024 | $235.7M | $162.7M | $557.4M | −8% |
| 2023 | $255.1M | $82.4M | $376.9M | −14% |
| 2022 | $297.2M | $236.7M | $894M | −68% |
| 2021 | $930.7M | $884.8M | $1.8B | −52% |
| 2020 | $1.9B | $1B | $2.1B | −11% |
| 2019 | $2.2B | $1.3B | $2.3B | +17% |
| 2018 | $1.9B | $1B | $3.1B | +88% |
| 2017 | $986.5M | $487.9M | $1B | +92% |
| 2016 | $513.4M | $513.4M | $849.6M | −47% |
| 2015 | $960.4M | $230.5M | $1.4B | +238% |
| 2014 | $284.5M | $138M | $353.5M | +97% |
| 2013 | $144.3M | $97.8M | $235.7M | −8% |
| 2012 | $157.1M | $50M | $166.2M | +242% |
| 2011 | $46M | $40M | $60M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Heron Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| HRTXHeron Therapeutics | $56M |
| SPROSpero Therapeutics | $60.6M |
| ATNMActinium Pharmaceuticals | $45M |
| LFVNLifevantage | $73.5M |
| NATRNatures Sunshine Products | $211.5M |
| CRMDCorMedix | $420.1M |
| ARVNArvinas | $491.7M |
| PBYIPuma Biotechnology | $525.5M |
| Peer median | $211.5M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Heron Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.